Description: Key Insights Using the 2 Stage Free Cash Flow to Equity, ResMed fair value estimate is US$257 ResMed's US$256 share...

Description: The Sleep Apnea Devices industry is set to grow from US$ 6.47 Billion in 2024 to an impressive US$ 12.23 Billion by 2033, at a CAGR of 7.32% from 2025 to 2033. This surge is driven by increasing sleep disorder rates, notably obstructive sleep apnea (OSA), due to factors like obesity and stress. Key growth drivers include heightened health awareness regarding untreated sleep apnea, enhanced healthcare infrastructure, and advances in sleep devices technology. The USA leads globally in market domin

Description: Ever wondered if ResMed stock is actually a steal or quietly overhyped? You're not alone. This article will dig beneath the surface to find out. Shares have seen modest gains recently, with the price up 2.6% over the past week and nearly 10% year-to-date. However, the last month saw a slight decline of 5.9%. Several headlines have been swirling around ResMed, from industry-wide updates in digital health and respiratory care to regulatory news shaping the medical device market. These stories...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: ResMed has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Description: The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and tariffs.

Description: ResMed Inc. ( NYSE:RMD ) shareholders might be concerned after seeing the share price drop 15% in the last quarter. On...

Description: INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and regi

Description: Exxon Mobil, Home Depot and NextEra Energy headline today's Zacks reports, each revealing key growth drivers and challenges shaping 2025 performance.

Description: Insiders were net sellers of ResMed Inc.'s ( NYSE:RMD ) stock during the past year. That is, insiders sold more stock...

Description: ResMed’s third quarter results aligned with Wall Street’s revenue expectations, while its non-GAAP earnings per share moderately outpaced consensus. Management attributed the quarter’s performance to robust demand for both devices and masks, particularly in the U.S., Canada, and Latin America, where mask resupply programs and new product launches drove growth. CEO Michael Farrell highlighted the contribution of recent acquisitions and continued investment in digital health, noting, “Our global t

Description: Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Description: Key opportunities in the UK sleep apnea devices market include leveraging rising demand for efficient healthcare, expanding AI and ML integration for personalized care, and catering to an aging, increasingly obese population. Emphasis on home-based diagnostics and therapy supports market growth. United Kingdom Sleep Apnea Devices Market United Kingdom Sleep Apnea Devices Market Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "United Kingdom Sleep Apnea Devices Market, By Region, Competition, Forec

Description: Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above analysts’ consensus estimates.

Description: RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.

Description: Let's talk about the popular ResMed Inc. ( NYSE:RMD ). The company's shares received a lot of attention from a...

Description: ResMed Inc (RMD) reports a robust quarter with 9% revenue growth, strategic product launches, and expansion in key markets despite facing industry challenges.

Description: While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: ResMed (RMD) delivered earnings and revenue surprises of +2.41% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: SAN DIEGO (AP) — ResMed Inc. RMD) on Thursday reported fiscal first-quarter net income of $348.5 million. On a per-share basis, the San Diego-based company said it had net income of $2.37.

Description: Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above analysts’ consensus estimates.

Description: Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE)

Description: Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: Medical device company ResMed (NYSE:RMD) will be reporting earnings this Thursday afternoon. Here’s what investors should know.

Description: Investors need to pay close attention to RMD stock based on the movements in the options market lately.

Description: Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 13.5% has lagged the S&P 500’s 22.9% climb.

Description: ResMed has seen its fair value estimate edge up slightly from $291.86 to $295.13, as recent improvements in margin expectations have contributed to this change. This modest increase comes amid ongoing shifts in both industry demand and company performance, reflecting a mix of optimism and caution in analyst sentiment. Stay tuned to discover how you can monitor these narrative changes and stay informed on future updates for ResMed stock. What Wall Street Has Been Saying 🐂 Bullish...

Description: ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: We came across a bullish thesis on ResMed Inc. on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.’s share was trading at $273.01 as of October 13th. RMD’s trailing and forward P/E were 29.09 and 25.91 respectively according to Yahoo Finance. ResMed (RMD) has quietly established itself as one of […]

Description: GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Description: Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.

Description: The global home healthcare market is projected to reach USD 473.8 billion by 2030, up from USD 309.9 billion in 2025, growing at a CAGR of 8.9%. This expansion is driven by rising lifestyle-related disorders such as high blood pressure, obesity, and cardiac conditions. Leading companies are innovating and introducing new home healthcare products. The therapeutic products segment holds the largest market share, fueled by a growing prevalence of chronic health conditions. Skilled nursing services

Description: PolyNovo (ASX:PNV) has appointed Robert Douglas to its Board of Directors, a move that brings decades of international medical device leadership into the mix. Investors are tuning in to see what his experience could mean for PolyNovo’s strategic direction. See our latest analysis for PolyNovo. PolyNovo’s recent board appointment arrives just as its share price faces volatility, slipping 20% over the past month and down nearly 39% year-to-date. Longer-term shareholders have felt the pressure...

Description: Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: PolyNovo Limited recently appointed Mr. Robert Douglas to its Board of Directors, bringing over thirty-five years of experience in medical device technology, digital health, and public company governance, with senior leadership roles at ResMed and board responsibilities at Globus Medical. This appointment introduces significant U.S. and Australian medtech expertise to PolyNovo’s leadership, potentially strengthening the company’s operational and strategic execution across its global...

Description: Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.

Description: Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.

Description: Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.